Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopharma Tax Strategy Demystified: A Q&A With Ernst & Young

Executive Summary

Several of this year’s biggest biopharma M&A deals provide significant tax benefits. “The Pink Sheet” brushes up on how multinational companies are managing tax considerations and examines more closely the core taxation issues for the industry.

You may also be interested in...



Elan’s Saga Comes To A Close With Perrigo’s $8.6 Billion Bid

Perrigo is using Elan’s beneficial tax rates to launch its international expansion and the royalty stream from Tysabri to help fund those M&A endeavors, but is not dramatically changing its OTC focus.

Sen. Baucus Still Has Ambitious Agenda: Tax Reform, Deficit Reduction, ACA

Finance Committee chairman decides not to seek re-election in 2014. He has a history of working productively with the drug industry on major legislation such as health reform, the Medicare Modernization Act and PDUFA reauthorizations.

Pharmas Among Biggest Cash Hoarders, Moody’s Finds

A Moody’s report lists seven pharmas among the 50 non-financial companies sitting on the largest piles of cash. These very big war chests hold the preferred currency, particularly for ex-U.S.pharma deal-making.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS055648

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel